[{"id":"e55df251-1fde-47bd-86f1-be2ff4bd4e5a","acronym":"VISTA","url":"https://clinicaltrials.gov/study/NCT03740256","created_at":"2021-01-18T18:19:18.650Z","updated_at":"2025-02-25T16:31:39.867Z","phase":"Phase 1","brief_title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","source_id_and_acronym":"NCT03740256 - VISTA","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT16"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2038","study_completion_date":" 12/30/2038","last_update_posted":"2025-02-07"},{"id":"a7bc29a2-9d83-422b-b210-345c766604ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03696030","created_at":"2021-01-18T18:06:55.252Z","updated_at":"2025-02-25T16:44:28.884Z","phase":"Phase 1","brief_title":"HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases","source_id_and_acronym":"NCT03696030","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-103"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/31/2018","start_date":" 08/31/2018","primary_txt":" Primary completion: 03/11/2025","primary_completion_date":" 03/11/2025","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-06"},{"id":"129e5cf7-9e95-4c6e-b07f-53ac9b2b4f09","acronym":"","url":"https://clinicaltrials.gov/study/NCT04511871","created_at":"2025-02-26T06:48:17.814Z","updated_at":"2025-02-26T06:48:17.814Z","phase":"Phase 1","brief_title":"A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors","source_id_and_acronym":"NCT04511871","lead_sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CCT303-406"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 03/29/2025","study_completion_date":" 03/29/2025","last_update_posted":"2024-10-28"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"d5526b73-7438-4fdc-91ed-4798a2bb9459","acronym":"","url":"https://clinicaltrials.gov/study/NCT06101082","created_at":"2023-10-25T19:14:21.944Z","updated_at":"2024-07-02T16:35:16.156Z","phase":"Phase 1","brief_title":"A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors","source_id_and_acronym":"NCT06101082","lead_sponsor":"China Medical University, China","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 01/16/2024","start_date":" 01/16/2024","primary_txt":" Primary completion: 10/19/2026","primary_completion_date":" 10/19/2026","study_txt":" Completion: 10/19/2026","study_completion_date":" 10/19/2026","last_update_posted":"2024-03-06"},{"id":"a18cecb1-f577-47bc-bd7c-470ec1fe494d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00902044","created_at":"2021-01-18T03:28:34.734Z","updated_at":"2024-07-02T16:35:23.626Z","phase":"Phase 1","brief_title":"Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","source_id_and_acronym":"NCT00902044","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AU-101 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/11/2010","start_date":" 02/11/2010","primary_txt":" Primary completion: 12/06/2019","primary_completion_date":" 12/06/2019","study_txt":" Completion: 07/01/2032","study_completion_date":" 07/01/2032","last_update_posted":"2024-01-12"},{"id":"fd9481d6-68fb-48f5-91be-f04325aa1f68","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389230","created_at":"2021-01-18T16:43:38.153Z","updated_at":"2024-07-02T16:35:24.644Z","phase":"Phase 1","brief_title":"Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma","source_id_and_acronym":"NCT03389230","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 06/14/2024","primary_completion_date":" 06/14/2024","study_txt":" Completion: 06/14/2024","study_completion_date":" 06/14/2024","last_update_posted":"2024-01-03"},{"id":"d14f485f-777a-43a1-8203-72839c6c8199","acronym":"","url":"https://clinicaltrials.gov/study/NCT03500991","created_at":"2021-01-18T17:14:31.303Z","updated_at":"2024-07-02T16:35:25.620Z","phase":"Phase 1","brief_title":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors","source_id_and_acronym":"NCT03500991","lead_sponsor":"Seattle Children's Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER2-Specific CAR T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/26/2018","start_date":" 07/26/2018","primary_txt":" Primary completion: 07/26/2024","primary_completion_date":" 07/26/2024","study_txt":" Completion: 07/26/2039","study_completion_date":" 07/26/2039","last_update_posted":"2023-12-20"},{"id":"6621b1d7-f94f-4b63-b32f-3acc54426d6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05681650","created_at":"2023-01-12T15:02:17.858Z","updated_at":"2024-07-02T16:35:26.470Z","phase":"Phase 1/2","brief_title":"HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors","source_id_and_acronym":"NCT05681650","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • HypoSti.CAR-HER2 T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-12"},{"id":"7b84f5ce-770d-4a13-9bc4-e1caa779cb8d","acronym":"iCAR","url":"https://clinicaltrials.gov/study/NCT02442297","created_at":"2021-01-18T11:42:04.422Z","updated_at":"2024-07-02T16:35:40.191Z","phase":"Phase 1","brief_title":"T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors","source_id_and_acronym":"NCT02442297 - iCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AU-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/01/2037","study_completion_date":" 04/01/2037","last_update_posted":"2023-08-14"},{"id":"9912c104-2619-4ba2-b95c-bb5c454672a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04650451","created_at":"2021-01-19T20:40:10.787Z","updated_at":"2024-07-02T16:35:49.989Z","phase":"Phase 1/2","brief_title":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","source_id_and_acronym":"NCT04650451","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • BPX-603"],"overall_status":"Suspended","enrollment":" Enrollment 220","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/02/2027","study_completion_date":" 01/02/2027","last_update_posted":"2023-04-20"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"9557a613-c303-410a-b30d-bcfd807825f2","acronym":"HERT-GBM","url":"https://clinicaltrials.gov/study/NCT01109095","created_at":"2021-01-18T04:23:31.492Z","updated_at":"2024-07-02T16:37:00.202Z","phase":"Phase 1","brief_title":"CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM","source_id_and_acronym":"NCT01109095 - HERT-GBM","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AU-105"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 03/07/2018","study_completion_date":" 03/07/2018","last_update_posted":"2019-04-25"},{"id":"bc600932-edcc-4a77-8717-8ae887e370be","acronym":"HERCREEM","url":"https://clinicaltrials.gov/study/NCT00889954","created_at":"2021-01-18T03:24:25.584Z","updated_at":"2024-07-02T16:37:06.790Z","phase":"Phase 1","brief_title":"Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy","source_id_and_acronym":"NCT00889954 - HERCREEM","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TGFBeta resistant HER2/EBV-CTLs"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/21/2018","study_completion_date":" 01/21/2018","last_update_posted":"2018-09-18"}]